Evidence map›Paper›PMID 42530137›Full record

ArticleJournal of clinical pharmacology2026

First-in-Human Study of a Long-Acting GLP-1 Receptor Agonist (TE-8105) in Overweight or Obese Adults Without Type 2 Diabetes Mellitus.

Ya-Shan Chuang, Jon D Wright, Mun-Teng Wong, Kushal J Paneliya, Wei-Shiung Yang, Hsing-Mao Chu, Tse Wen Chang, Thomas M Polasek

Abstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ya-Shan ChuangImmunwork, Inc., Taipei City, Taiwan.
Jon D WrightImmunwork, Inc., Taipei City, Taiwan.
Mun-Teng WongImmunwork, Inc., Taipei City, Taiwan.
Kushal J PaneliyaCMAX Clinical Research Pty Ltd, Adelaide, Australia.
Wei-Shiung YangDepartment of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan.
Hsing-Mao ChuImmunwork, Inc., Taipei City, Taiwan.
Tse Wen ChangImmunwork, Inc., Taipei City, Taiwan.
Thomas M PolasekCMAX Clinical Research Pty Ltd, Adelaide, Australia.

Funding

Immunwork, Inc
6 · The paper itself

Abstract

Glucagon-like peptide-1 (GLP-1) receptor agonists have revolutionized weight management and are becoming essential for the treatment of obesity-related medical conditions. This study aimed to determine the pharmacokinetics, preliminary pharmacodynamics, safety, and tolerability of a long-acting GLP-1 receptor agonist, TE-8105, in overweight or obese adults without T2DM. An open-label study of four single ascending dose cohorts (A1-A4, 0.5, 0.75, 1.5, and 3.0 mg TE-8105, respectively) and two multiple dose cohorts (B1 flat dosing, 1.0 mg TE-8105 Q2W SC for 5 doses, and B2 titration dosing, sequence 2 × 1.5, 2 × 2.0, 2 × 2.5, and 3 × 3.0 mg Q2W SC) was conducted using a combination of in-patient and out-patient assessments. The half-life of TE-8105 was about 120 h. There was no accumulation after flat dosing, but mean (SD) accumulation ratios were 3.75 (0.86) for C

Indexed as

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsObesityOverweightAdultAgedDiabetes Mellitus, Type 2Dose-Response Relationship, DrugFemaleHalf-LifeHumansMaleMiddle AgedYoung AdultGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsGLP‐1 receptor agonistslong‐actingoverweight/obeseTE‐8105weight loss

Identifiers

PMID42530137
PMCPMC13421993

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.